Aviram Joshua, Lewitus Gil M, Vysotski Yelena, Amna Mahmoud Abu, Ouryvaev Anton, Procaccia Shiri, Cohen Idan, Leibovici Anca, Akria Luiza, Goncharov Dimitry, Mativ Neomi, Kauffman Avia, Shai Ayelet, Bar-Sela Gil, Meiri David
Faculty of Biology, Biology Department, Technion-Israel Institute of Technology, Haifa, Israel.
Cancer Center, HaEmek Medical Center, Afula, Israel.
Front Pain Res (Lausanne). 2022 May 20;3:861037. doi: 10.3389/fpain.2022.861037. eCollection 2022.
The use of medical cannabis (MC) to treat cancer-related symptoms is rising. However, there is a lack of long-term trials to assess the benefits and safety of MC treatment in this population. In this work, we followed up prospectively and longitudinally on the effectiveness and safety of MC treatment. Oncology patients reported on multiple symptoms before and after MC treatment initiation at one-, three-, and 6-month follow-ups. Oncologists reported on the patients' disease characteristics. Intention-to-treat models were used to assess changes in outcomes from baseline. MC treatment was initiated by 324 patients and 212, 158 and 126 reported at follow-ups. Most outcome measures improved significantly during MC treatment for most patients ( < 0.005). Specifically, at 6 months, total cancer symptoms burden declined from baseline by a median of 18%, from 122 (82-157) at baseline to 89 (45-138) at endpoint (-18.98; 95%CI= -26.95 to -11.00; < 0.001). Reported adverse effects were common but mostly non-serious and remained stable during MC treatment. The results of this study suggest that MC treatment is generally safe for oncology patients and can potentially reduce the burden of associated symptoms with no serious MC-related adverse effects.
使用医用大麻(MC)治疗癌症相关症状的情况正在增加。然而,缺乏长期试验来评估MC治疗在该人群中的益处和安全性。在这项研究中,我们对MC治疗的有效性和安全性进行了前瞻性和纵向随访。肿瘤患者在开始MC治疗前以及治疗后1个月、3个月和6个月的随访中报告了多种症状。肿瘤学家报告了患者的疾病特征。采用意向性分析模型评估与基线相比的结局变化。324例患者开始MC治疗,212例、158例和126例患者在随访时进行了报告。大多数患者在MC治疗期间,大多数结局指标有显著改善(<0.005)。具体而言,在6个月时,癌症症状总负担较基线下降,中位数为18%,从基线时的122(82-157)降至随访结束时的89(45-138)(-18.98;95%CI=-26.95至-11.00;<0.001)。报告的不良反应很常见,但大多不严重,且在MC治疗期间保持稳定。本研究结果表明,MC治疗对肿瘤患者总体安全,且可能减轻相关症状负担,未出现与MC相关的严重不良反应。